Skip to main content
SpringerLink
Log in

Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Better postoperative management of patients who have undergone single ventricle (SV) Fontan procedure could potentially reduce long-term complications and improve the quality of life for patients. The present study determined the effect of tadalafil on myocardial and endothelial function and exercise performance after modified Fontan operation. Patients who had undergone SV modified Fontan operation were enrolled in this clinical trial. The demographic characteristics of the patients were recorded. Before administration of tadalafil and after the trial, ventricular function (MPI, EF, FS, E/A, VTI), exercise performance, and endothelial function were evaluated for sonographic and biochemical markers (FMD, IMT, ICAM, VCAM, NO) using echocardiography, exercise testing, vascular ultrasonography, and biochemical measurements, respectively. A single dose of tadalafil of 1 mg/kg was administered daily for 6 weeks, and the functional class of the patients before and after tadalafil was determined. A total of 15 patients completed this clinical trial. Tadalafil was shown to have a significant effect on myocardial function, exercise performance, and improvement in NYHA functional class (p < 0.05) of study population. It had no significant effect on the biochemical variables and endothelial function except for IMT (p > 0.05), which decreased significantly after tadalafil administration (p < 0.05). The findings indicate that tadalafil is a safe, well-tolerated agent for the use after modified Fontan operation to improve myocardial function and exercise performance and possibly reduce long-term morbidity and mortality of patients. More conclusive results could be obtained from further study with a larger sample size and long-term follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Affuso F, Palmieri EA, Di Conza P (2006) Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 108(3):429–431

    Article  PubMed  Google Scholar 

  2. Al-Mousawi NRH, Al Hakim AH (2008) A study of the effect of phosphodiesterase-5-inhibitor on serum lipid profile in the male rats. Kufa Med J 11(1):277–282

    Google Scholar 

  3. Arif SA, Poon H (2011) Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther 33(8):993–1004

    Article  CAS  PubMed  Google Scholar 

  4. Bharani A, Patel A, Saraf J et al (2007) Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J 59(4):323–328

    PubMed  Google Scholar 

  5. Chungsomprasong P, Soongswang J, Nana A et al (2011) Medium and long-term outcomes of Fontan operation. J Med Assoc Thai 94(3):323–330

    PubMed  Google Scholar 

  6. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D (2002) International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39(2):257–265

    Article  PubMed  Google Scholar 

  7. de Vivie ER, Rupprath G (1986) Long-term results after Fontan procedure and its modifications. J Thorac Cardiovasc Surg 91(5):690–697

    PubMed  Google Scholar 

  8. Deal BJ, Jacobs ML (2012) Management of the failing Fontan circulation. Heart 98(14):1098–1104

    Article  PubMed Central  PubMed  Google Scholar 

  9. Forgue ST, Patterson BE, Bedding AW et al (2006) Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 61(3):280–288

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Fredenburg TB, Johnson TR, Cohen MD (2011) The Fontan procedure: anatomy, complications, and manifestations of failure. Radiographics 31(2):453–463

    Article  PubMed  Google Scholar 

  11. Galie N, Brundage BH, Ghofrani HA et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894–2903

    Article  CAS  PubMed  Google Scholar 

  12. Giannetta E, Feola T, Gianfrilli D et al (2014) Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 12(1):185

    Article  PubMed Central  PubMed  Google Scholar 

  13. Goldberg DJ, Shaddy RE, Ravishankar C et al (2011) The failing Fontan: etiology, diagnosis and management. Expert Rev Cardiovasc Ther 9(6):785–793

    Article  PubMed  Google Scholar 

  14. Hill KD, Tunks RD, Barker PC et al (2013) Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med 14(6):593–600

    Article  PubMed Central  PubMed  Google Scholar 

  15. Jackson G (2005) Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 96(12B):32M–36M

    Article  CAS  PubMed  Google Scholar 

  16. Karatza AA, Bush A, Magee AG (2005) Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 100(2):267–273

    Article  PubMed  Google Scholar 

  17. Lai WW, Geva T, Shirali GS et al (2006) Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr 19:1413–1430

    Article  PubMed  Google Scholar 

  18. Meyer AA, Kundt G, Steiner M (2006) Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics 117(5):1560–1567

    Article  PubMed  Google Scholar 

  19. Rao YJ, Xi L (2009) Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 30(1):1–24

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Rosano GM, Aversa A, Vitale C et al (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47(2):214–220 (discussion 220–2)

    Article  CAS  PubMed  Google Scholar 

  21. Roumeguère T, Zouaoui Boudjeltia K, Hauzeur C et al (2008) Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers. Prog Urol 18(13):1087–1091

    Article  PubMed  Google Scholar 

  22. Rychik J (2010) Forty years of the Fontan operation: a failed strategy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 13:96–100

    Article  PubMed  Google Scholar 

  23. Sabri MR, Beheshtian E (2014) Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr Cardiol 35(4):699–704

    Article  PubMed  Google Scholar 

  24. Senzaki H, Masutani S, Ishido H, Kobayashi J, Kobayashi T, Sasaki N et al (2002) Ventricular afterload and ventricular work in Fontan circulation: comparison with normal two-ventricle circulation and single ventricle circulation with Blalock–Taussig shunts. Circulation 105:2885–2892

    Article  PubMed  Google Scholar 

  25. Takatsuki S, Calderbank M, Ivy DD (2012) Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 33(5):683–688

    Article  PubMed Central  PubMed  Google Scholar 

  26. Teloken PE, Mulhall JP (2008) Impact of phosphodiesterase type 5 inhibitors on endothelial function. Rev Urol 10(1):26–30

    PubMed Central  PubMed  Google Scholar 

  27. Trojnarska O, Ciepłucha A (2011) Challenges of management and therapy in patients with a functionally single ventricle after Fontan operation. Cardiol J 18(2):119–127

    PubMed  Google Scholar 

  28. Tunks RD, Barker PC, Benjamin DK Jr et al (2014) Sildenafil exposure and hemodynamic effect after Fontan surgery. Pediatr Crit Care Med 15(1):28–34

    Article  PubMed  Google Scholar 

  29. Washington SL 3rd, Shindel AW (2010) A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther 4:159–171

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isfahan University of Medical Sciences, Isfahan, Iran

    Mohammad-Reza Sabri, Ali Zolfi-Gol, Alireza Ahmadi & Shaghayegh Haghjooy-Javanmard

Authors
  1. Mohammad-Reza Sabri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Zolfi-Gol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shaghayegh Haghjooy-Javanmard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Zolfi-Gol.

Ethics declarations

Conflict of interest

Authors declare they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sabri, MR., Zolfi-Gol, A., Ahmadi, A. et al. Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation. Pediatr Cardiol 37, 55–61 (2016). https://doi.org/10.1007/s00246-015-1238-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-015-1238-x

Keywords

Search

Navigation